In this study we investigated the prognostic value of immune cell density and Immunogradient indicators for CD8+, CD20+ and CD68+ in the context of MSI status and a variety of clinicopathological and molecular features in a selected CRC patient cohort. The gene discussed is CD8A; the disease is colorectal carcinoma.